Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
HSA approves Pfizer’s new RSV vaccine
This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical protection to infants and seniors
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.
ENDPOINTS NEWS3m
Pfiz­er culls RSV treat­ment from Re­Vi­ral ac­qui­si­tion
Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
STAT4d
After a rocky debut for new RSV tools, hopes are high as a new season approaches
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say
Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make ...
Benzinga.com1d
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer's legal win invalidates two GSK patents in UK RSV vaccine case. On Monday, Pfizer Inc. PFE stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro.
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
KSL3d
What to know about the RSV immunization for babies
As many as 80,000 children under 5 are hospitalized each year due to the respiratory syncytial virus, according to the CDC.